Ishara Investments LP
LOS ANGELES, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$119.5M2026 Q3+ $1.5M options (notional, not included)
Positions41
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.49.6%
Top Holdings
TVTX
Travere Therapeutics
7.1%
CYTK
Cytokinetics
7.0%
BBIO
BridgeBio Pharma
5.4%
ACAD
Acadia Pharmaceuticals
5.3%
TARS
Tarsus Pharmaceuticals
4.5%
PTCT
PTC Therapeutics
4.3%
PRAX
Praxis Precision Medicines
4.1%
VERA
Vera Therapeutics
4.0%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.